DiaSorin and Beckman Coulter Form Strategic Partnership to Bring the Liaison XL Hepatitis and HIV Products to the U.S. Market


SALUGGIA (VC) and BREA, Calif. (USA) — (August 30, 2016) — DiaSorin (FTSE Italia Mid Cap: DIA), a global leader in in vitro diagnostics immunoassay specialty testing, and Beckman Coulter Diagnostics, a global developer and manufacturer of clinical diagnostic products, are pleased to announce an agreement to provide customers in the U.S. the LIAISON XL Hepatitis A, B, C and HIV products currently available to DiaSorin customers outside the U.S. territory. The two companies will work together to submit the products to the Food and Drug Administration (FDA) for approval and commercialization in the U.S.

Once cleared, Beckman Coulter and DiaSorin intend to offer U.S. customers access to the full line of Hepatitis and HIV products that can be run on the LIAISON XL LAS connected to Beckman Coulter's leading automation solutions, the Power Express and Power Processor automated processing systems. According to the agreement, DiaSorin will retain the right to commercialize the products on LIAISON XL stand-alone systems, to pursue its strategy of penetrating the lower volume hospital labs where total laboratory automation (TLA) is not required.

DiaSorin estimates that the total available U.S. market for these products, excluding blood bank testing, exceeds U.S. $500 million.

"After the successful agreement we already signed in China, I'm very proud that Beckman Coulter choose to extend the partnership with us to the U.S. market," commented Carlo Rosa, CEO of DiaSorin Group. "Our complete menu of Hepatitis and HIV products available on the LIAISON XL coupled with the Beckman Coulter leadership in the TLA market will offer our customers an ideal solution to address the issues created in the labs by the increase of testing volume related to the ongoing consolidation of testing sites."

"Beckman Coulter and DiaSorin have been working successfully together in China since late last year, helping our customers improve their operations in this key testing area. This new agreement is a natural extension of that partnership. Beckman Coulter is very pleased to be working so close with DiaSorin to bring to our customers solutions for their laboratories," said Arnd Kaldowski, president, Beckman Coulter Diagnostics. 

About DiaSorin
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the Diagnostic field. For over 40 years, the Company has been investing to develop, produce and sell tests that answer to the worldwide laboratories' needs. The continuous focus on innovation enables the DiaSorin Group to be identified as "the Diagnostic specialist". For further information, please visit www.diasorin.com.

About Beckman Coulter
For more than 80 years, Beckman Coulter has been the partner of choice for laboratory professionals. Beckman Coulter Diagnostics is dedicated to helping healthcare professionals deliver better patient care, improved quality and lower costs by giving them accurate diagnostic information. The company delivers a comprehensive portfolio of high quality, connected, diagnostic solutions. The combination of our scalable instrument portfolio with our automated and integrated data management systems and broad assay menu allows customers to achieve productivity throughout their organizations and improve patient care. Supporting clinicians' and physicians' goal of delivering excellent patient care is at the heart of all we do. Beckman Coulter is, and always has been, singularly devoted to advancing healthcare for every person. For more information, visit www.beckmancoulter.com.

For additional information, please contact:
For DiaSorin
Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel. +39.0161.487988

Ines Di Terlizzi
Investor Relator
Tel. +39.0161.487567

For Beckman Coulter
Mary Luthy
Director, Corporate Communications

Roslyn Whitehurst
Global Media Relations